Envisia Therapeutics To Present At ARVO 2016 Annual Meeting

Sunday, May 1, 2016 General News J E 4
Company to Deliver Eight Data Presentations at World's Largest Ophthalmology Gathering

RESEARCH TRIANGLE PARK, N.C., May 1, 2016 /PRNewswire/ -- Envisia Therapeutics today announced that eight posters have been selected for presentation at the Association for Research in Vision and Ophthalmology's (ARVO) Annual Meeting being held May 1 – 5, 2016 in Seattle, WA. ARVO is the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries. The theme of the ARVO 2016 Annual Meeting is Research: A vision for hope.

"ARVO continues to be the preeminent venue for scientific exchange in ophthalmology and we are very pleased to be able to present a comprehensive array of data from our pipeline programs," said Benjamin Yerxa, PhD, President of Envisia Therapeutics. "We are incredibly proud of the progress we have made and welcome the opportunity to showcase that progress at this world renowned meeting."

Details related to Envisia presentations at ARVO are as follows:

Sunday, May 1, 2016

Poster #A0164: Extended Release of anti-VEGF Biologics from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration

  • Exhibit Hall, AMD and Anti-VEGF Therapy, 1:30pm3:15pm, Sunday, May 1, 2016
  • Presented by Gary Owens, MS – Principal Scientist, Analytical Sciences

Tuesday, May 3, 2016

Poster #A0374: Completed 28-Day and Ongoing 12-Month Safety and Efficacy Evaluation of ENV515 (travoprost) Intracameral Implant in Phase 2 Study

  • Exhibit Hall, Glaucoma Clinical Studies/Pharmacology, 8:30am - 10:15am, Tuesday, May 3, 2016
  • Presented by Dr. Thomas R. Walters, MD – Texan Eye/Keystone Research, Austin TX

Poster #A0370: Design and Development of ENV515 Intraocular Applicator for Intracameral Injections of ENV515 Glaucoma Extended Release (XR) Therapy

  • Exhibit Hall, Glaucoma Clinical Studies/Pharmacology, 8:30am - 10:15am, Tuesday, May 3, 2016
  • Presented by Tomas Navratil, PhD – Senior Vice President, Development

Poster #C0078: Precision Size and Shape Extended Release Intravitreal Dexamethasone Implants

  • Exhibit Hall, Diabetic Retinopathy and Steroids, 8:30am - 10:15am, Tuesday, May 3, 2016
  • Presented by Sanjib K. Das, PhD – Sr. Principal Scientist, Research

Poster #B0191: A 6-Week Toxicity and Toxicokinetics Study of a Single Bilateral Intracameral Administration of ENV905 (difluprednate) Ophthalmic Implant in New Zealand White Rabbits  

  • Exhibit Hall, Drug Delivery, 3:45pm5:30pm Tuesday, May 3, 2016
  • Presented by RiLee Robeson – Manager, Nonclinical Development

Poster #B0201: In vitro and In vivo Sustained Release of Dexamethasone from a PRINT Microparticle Suspension

  • Exhibit Hall, Drug Delivery, 3:45pm - 5:30pm, Tuesday, May 3, 2016
  • Presented by Melissa Sandahl , MS – Scientist, Research

Poster #B0207: Sustained Release Biodegradable Formulations for Intraocular Delivery: Extended Release of Hydrophilic APIs and Combination Products

  • Exhibit Hall, Drug Delivery, 3:45pm5:30pm, Tuesday, May 3, 2016
  • Presented by Janet Tully – Senior Scientist, Analytical

Thursday, May 5, 2016

Poster #A0099: A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit

  • Exhibit Hall, Cornea Disease Therapy,  8:00am – 9:45am, Thursday, May 5, 2016
  • Presented by Rozemarijn Verhoeven, MS – Executive Director, Nonclinical Development

ABOUT ENVISIA THERAPEUTICS™Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. In January 2015, the company initiated a phase 2a clinical trial to investigate the safety and tolerability of ENV515 in patients with glaucoma.

Envisia is located in Research Triangle Park, North Carolina. For more information, please go to

To view the original version on PR Newswire, visit:

SOURCE Envisia Therapeutics



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
The ALS Association and Cytokinetics Ring in May a...
Optimizing a New Pharmaceutical Product's Market E...